NM_012434.5:c.406A>G

Variant summary

Our verdict is Pathogenic. The variant received 14 ACMG points: 14P and 0B. PM2PM5PP3_ModeratePP5_Very_Strong

The NM_012434.5(SLC17A5):​c.406A>G​(p.Lys136Glu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000874 in 1,614,010 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. K136R) has been classified as Likely pathogenic.

Frequency

Genomes: 𝑓 0.000072 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000089 ( 0 hom. )

Consequence

SLC17A5
NM_012434.5 missense

Scores

11
6
1

Clinical Significance

Pathogenic criteria provided, multiple submitters, no conflicts P:15O:1

Conservation

PhyloP100: 7.48

Publications

27 publications found
Variant links:
Genes affected
SLC17A5 (HGNC:10933): (solute carrier family 17 member 5) This gene encodes a membrane transporter that exports free sialic acids that have been cleaved off of cell surface lipids and proteins from lysosomes. Mutations in this gene cause sialic acid storage diseases, including infantile sialic acid storage disorder and and Salla disease, an adult form. [provided by RefSeq, Jul 2008]
SLC17A5 Gene-Disease associations (from GenCC):
  • free sialic acid storage disease
    Inheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
  • Salla disease
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: G2P, Orphanet, Genomics England PanelApp, Myriad Women’s Health
  • free sialic acid storage disease, infantile form
    Inheritance: AR Classification: STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae), Orphanet
  • intermediate severe Salla disease
    Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Pathogenic. The variant received 14 ACMG points.

PM2
Very rare variant in population databases, with high coverage;
PM5
Other missense variant is known to change same aminoacid residue: Variant chr6-73641809-T-C is described in ClinVar as Likely_pathogenic. ClinVar VariationId is 2068802.Status of the report is criteria_provided_single_submitter, 1 stars.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.938
PP5
Variant 6-73641810-T-C is Pathogenic according to our data. Variant chr6-73641810-T-C is described in ClinVar as Pathogenic. ClinVar VariationId is 21493.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.

Variant Effect in Transcripts

ACMG analysis was done for transcript: NM_012434.5. You can select a different transcript below to see updated ACMG assignments.

RefSeq Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
SLC17A5
NM_012434.5
MANE Select
c.406A>Gp.Lys136Glu
missense
Exon 3 of 11NP_036566.1
SLC17A5
NM_001382633.1
c.406A>Gp.Lys136Glu
missense
Exon 3 of 12NP_001369562.1
SLC17A5
NM_001382631.1
c.427A>Gp.Lys143Glu
missense
Exon 4 of 12NP_001369560.1

Ensembl Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
SLC17A5
ENST00000355773.6
TSL:1 MANE Select
c.406A>Gp.Lys136Glu
missense
Exon 3 of 11ENSP00000348019.5
SLC17A5
ENST00000481996.1
TSL:4
n.172A>G
non_coding_transcript_exon
Exon 2 of 5

Frequencies

GnomAD3 genomes
AF:
0.0000724
AC:
11
AN:
152012
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0000483
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000197
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000882
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.0000318
AC:
8
AN:
251472
AF XY:
0.0000368
show subpopulations
Gnomad AFR exome
AF:
0.0000615
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.0000544
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000440
Gnomad OTH exome
AF:
0.000163
GnomAD4 exome
AF:
0.0000889
AC:
130
AN:
1461880
Hom.:
0
Cov.:
31
AF XY:
0.0000990
AC XY:
72
AN XY:
727242
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
33480
American (AMR)
AF:
0.0000224
AC:
1
AN:
44724
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26136
East Asian (EAS)
AF:
0.0000756
AC:
3
AN:
39698
South Asian (SAS)
AF:
0.0000116
AC:
1
AN:
86258
European-Finnish (FIN)
AF:
0.0000562
AC:
3
AN:
53418
Middle Eastern (MID)
AF:
0.000173
AC:
1
AN:
5768
European-Non Finnish (NFE)
AF:
0.0000944
AC:
105
AN:
1112002
Other (OTH)
AF:
0.000265
AC:
16
AN:
60396
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.487
Heterozygous variant carriers
0
7
14
22
29
36
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
10
20
30
40
50
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0000723
AC:
11
AN:
152130
Hom.:
0
Cov.:
32
AF XY:
0.0000538
AC XY:
4
AN XY:
74352
show subpopulations
African (AFR)
AF:
0.0000482
AC:
2
AN:
41506
American (AMR)
AF:
0.000196
AC:
3
AN:
15272
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3468
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5170
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4814
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10584
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.0000882
AC:
6
AN:
67998
Other (OTH)
AF:
0.00
AC:
0
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.539
Heterozygous variant carriers
0
1
2
4
5
6
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0000529
Hom.:
0
Bravo
AF:
0.000117
ExAC
AF:
0.0000247
AC:
3
EpiCase
AF:
0.000109
EpiControl
AF:
0.000119

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:15Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Salla disease Pathogenic:9
Sep 16, 2020
Natera, Inc.
Significance:Pathogenic
Review Status:no assertion criteria provided
Collection Method:clinical testing

Mar 30, 2014
Counsyl
Significance:Likely pathogenic
Review Status:no assertion criteria provided
Collection Method:literature only

This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com.

Aug 26, 2020
New York Genome Center
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Feb 24, 2025
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant summary: SLC17A5 c.406A>G (p.Lys136Glu) results in a conservative amino acid change located in the Major facilitator superfamily domain (IPR020846) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 3.2e-05 in 251472 control chromosomes (gnomAD). c.406A>G has been reported in the literature in individuals affected with Salla disease (Morin_2004, Mochel_2009). These data indicate that the variant is likely to be associated with disease. Multiple publications reported experimental evidence evaluating an impact on protein function and this variant affected the SLC17A5 protein function (Miyaji_2011, Morin_2004, Wreden_2005). The following publications have been ascertained in the context of this evaluation (PMID: 21781115, 20101035, 15510212, 15516337). ClinVar contains an entry for this variant (Variation ID: 21493). Based on the evidence outlined above, the variant was classified as pathogenic.

Sep 26, 2019
Biochemical Molecular Genetic Laboratory, King Abdulaziz Medical City
Significance:Pathogenic
Review Status:no assertion criteria provided
Collection Method:clinical testing

Feb 16, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change replaces lysine, which is basic and polar, with glutamic acid, which is acidic and polar, at codon 136 of the SLC17A5 protein (p.Lys136Glu). This variant is present in population databases (rs80338795, gnomAD 0.007%). This missense change has been observed in individuals with SLC17A5-related conditions (PMID: 10947946, 16170568, 19557856). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 21493). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SLC17A5 protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects SLC17A5 function (PMID: 15510212, 15516337, 21781115). For these reasons, this variant has been classified as Pathogenic.

Jan 23, 2024
Baylor Genetics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Dec 01, 2005
OMIM
Significance:Pathogenic
Review Status:no assertion criteria provided
Collection Method:literature only

Sep 05, 2021
Genome-Nilou Lab
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

not provided Pathogenic:4
Mar 01, 2023
CeGaT Center for Human Genetics Tuebingen
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

SLC17A5: PM3:Strong, PS4, PM2, PS3:Supporting

Nov 12, 2023
GeneDx
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Published functional studies demonstrate approximately 10% residual enzyme activity compared to wild-type, similar to the R39C variant, the common variant associated with Salla disease (PMID: 15516337); Another published functional study found that K136E mutant sialin protein did not transport aspartate and glutamate; however, H+/sialic acid co-transport activity was 50% of the wild-type protein, which was also similar to the results seen for the R39C variant (PMID: 21781115); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 10947946, 19557856, 15510212, 33862140, 16170568, 32371413, 32608236, 36662855, 37713976, 37272184, 21781115, 15516337)

Nov 08, 2019
Revvity Omics, Revvity
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Oct 06, 2023
Mayo Clinic Laboratories, Mayo Clinic
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

PP1_strong, PP3, PM2_moderate, PM3_very_strong, PS3, PS4_moderate

Sialic acid storage disease, severe infantile type;C1096903:Salla disease Pathogenic:2
Feb 20, 2018
Institute for Genomic Medicine (IGM) Clinical Laboratory, Nationwide Children's Hospital
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

[ACMG/AMP: PS3, PM2, PS4_Moderate, PP3, PP5] This alteration is supported by well-established in vitro or in vivo functional studies to have a damaging effect on protein function or splicing [PS3], is absent from or rarely observed in large-scale population databases [PM2], has previously been observed in multiple unrelated patients with the same phenotype [PS4_Moderate], is predicted to be damaging by multiple functional prediction tools [PP3], was reported as a pathogenic/likely pathogenic alteration by a reputable source (ClinVar or other correspondence from a clinical testing laboratory) [PP5].

Oct 31, 2018
Fulgent Genetics, Fulgent Genetics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Sialic acid storage disease, severe infantile type Other:1
GeneReviews
Significance:not provided
Review Status:no classification provided
Collection Method:literature only

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.74
BayesDel_addAF
Pathogenic
0.23
D
BayesDel_noAF
Pathogenic
0.27
CADD
Pathogenic
28
DANN
Pathogenic
1.0
DEOGEN2
Pathogenic
0.80
D
Eigen
Pathogenic
0.91
Eigen_PC
Pathogenic
0.86
FATHMM_MKL
Pathogenic
0.98
D
LIST_S2
Uncertain
0.89
D
M_CAP
Benign
0.083
D
MetaRNN
Pathogenic
0.94
D
MetaSVM
Uncertain
0.036
D
MutationAssessor
Pathogenic
4.1
H
PhyloP100
7.5
PrimateAI
Uncertain
0.50
T
PROVEAN
Uncertain
-3.4
D
REVEL
Pathogenic
0.75
Sift
Uncertain
0.0030
D
Sift4G
Uncertain
0.047
D
Polyphen
1.0
D
Vest4
0.98
MVP
0.92
MPC
0.87
ClinPred
0.98
D
GERP RS
5.8
Varity_R
0.94
gMVP
0.93
Mutation Taster
=5/95
disease causing (ClinVar)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs80338795; hg19: chr6-74351533; COSMIC: COSV63289145; API